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To characterise plasmodial glycolysis, we generated two transgenic Plasmodium falciparum lines,
one expressing P. falciparum hexokinase (PfHK) tagged with GFP (3D7-PfHKGFP) and another over-
expressing native PfHK (3D7-PfHK+). Contrary to previous reports, we propose that PfHK is cytosolic.
The glucose analogue, 2-deoxy-D-glucose (2-DG) was nearly 2-fold less toxic to 3D7-PfHK+ compared
with control parasites, supporting PfHK as a potential drug target. Although PfHK activity was
higher in 3D7-PfHK+, they accumulated phospho-[14C]2-DG at the same rate as control parasites.
Transgenic parasites overexpressing the parasite’s glucose transporter (PfHT) accumulated phos-
pho-[14C]2-DG at a higher rate, consistent with glucose transport limiting glucose entry into
glycolysis.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Malaria is an important parasitic infection caused by members
of the genus Plasmodium. It is one of the leading causes of morbid-
ity and mortality in the world with 3.1 billion people at risk of
being infected [1]. Plasmodium falciparum is the most virulent spe-
cies infecting humans.
Due to the dependence of blood-stage P. falciparum on glycoly-
sis for its ATP requirement [2], the pathway represents an attrac-
tive target for the development of new and much-needed
antimalarials. Glucose entry into the parasite is mediated by the
P. falciparum hexose transporter, PfHT, a facilitative and saturable
transport protein located on the parasite’s plasma membrane [3–
5]. Glucose transport by PfHT has been validated chemically and
genetically as an antimalarial drug target. Previous investigations
have shown that PfHT activity can be potently and selectively
inhibited by a series of O-3 (including compound 3361) and O-2
D-glucose derivatives [5–7]. Compound 3361 causes parasitegrowth inhibition in vivo in Plasmodium berghei-infected rodents
[6] and, more recently, has been shown to inhibit liver and trans-
mission stages of the murine malarial parasite [8]. Once inside
the parasite, glucose is phosphorylated in the cytoplasm by a hexo-
kinase, PfHK, the ﬁrst enzyme in the glycolytic pathway [9]. De-
spite its importance to the parasite, little is known about PfHK.
The 55.3 kDa protein is encoded by a single intron-less gene lo-
cated on chromosome 6 [10,11] and has been shown to have a low-
er afﬁnity for glucose compared with the host erythrocyte
hexokinase [9]. Using microscopy data, Olafsson and Certa sug-
gested that PfHK is associated with the parasite plasma membrane
(PPM) [12]. This localisation is supported by the presence of a po-
tential hydrophobic membrane anchor sequence at the protein’s
carboxy terminus [10].
Previous studies have also demonstrated PfHK as a potential
drug target. Early experiments showed that two glucose analogues,
2-deoxy-D-glucose (2-DG) and 2-ﬂuoro-2-deoxy-D-glucose (2-FG),
inhibited parasite glycosylation and, as a result, parasite growth
[13–15]. A subsequent study further described the antiplasmodial
effects of 2-DG and 2-FG [16]. The analogues inhibited P. falciparum
proliferation with increased potency under low glucose conditions,
consistent with inhibition of the parasite’s metabolism of glucose.
Results of subsequent experiments indicated that the analogues
exert their antiplasmodial activity, at least partly, by inhibiting glu-
cose phosphorylation. They likely carry this out by acting as PfHK
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known to be phosphorylated by PfHK [17] and the human hexoki-
nase, respectively [18]. However, the exact mechanism by which
they inhibit parasite growth is still unclear.
In this study we show that PfHK is located throughout the par-
asite cytosol and that overexpression of PfHK renders the parasites
resistant to 2-DG compared with wild-type parasites, consistent
with PfHK being the target of 2-DG and, therefore, a potential
antimalarial drug target. Furthermore, by measuring 2-DG phos-
phorylation and accumulation rates in transgenic parasites over-
expressing PfHK and PfHT, we present data consistent with the
transport of glucose into the parasite by PfHT limiting the rate of
glucose entry into P. falciparum glycolysis.2. Materials and methods
2.1. Parasite culture, lysate preparation and transfection
Intraerythrocytic P. falciparum parasites (3D7 strain and subse-
quent transfectants) were cultured, synchronised and isolated as
described previously [19] with minor modiﬁcations (Supplemen-
tary information). Parasite lysates were prepared from saponin-
isolated parasites as described previously [20] with somemodiﬁca-
tions. Isolated parasites were placed in 15 ml tubes and triturated
through a 25-gauge SafetyGlide needle (BD) to reduce the risk of
needle-stick injuries. Lysates were divided into 150 ll aliquots
and stored at 20 C until required. Parasites were transfected by
electroporation as previously described [21] with modiﬁcations
(Supplementary information).
2.2. Recombinant plasmid construct
PfHK-speciﬁc sequence was ampliﬁed from P. falciparum gDNA
via PCR using KOD Hot Start DNA Polymerase (Novagen). The oligo-
nucleotides and the PCR settings are shown in Supplementary
information. Restriction enzyme-digested inserts were ligated into
pGlux-1 using the Quick Ligation Kit (New England Biolabs). RbCl-
competent Escherichia coli cells were transformed with the recom-
binant plasmids as previously described for CaCl2-competent cells
[22] and transformants selected using ampicillin. Plasmid DNA
sequencing was carried out at the Australian Genome Research
Facility (Sydney).
2.3. Confocal microscopy
3D7-PfHKGFP-infected erythrocytes (10–15% parasitaemia, 4%
haematocrit, 5–10 ll) were examined live, and images of the cells
captured, with a Zeiss LSM 780 confocal microscope (Carl Zeiss
MicroImaging GmbH), at the Centre for Advanced Microscopy,
The Australian National University, using a 40 water immersion
or 100  oil immersion lens.
2.4. Flow cytometry
To determine the percentage of ﬂuorescent 3D7-PfHKGFP
parasites, saponin-isolated 3D7 (used to establish level of auto-
ﬂuorescence) and 3D7-PfHKGFP trophozoites were analysed by
FACS. Isolated parasites were suspended in standard malaria
saline (125 mM NaCl, 5 mM KCl, 25 mM HEPES, 20 mM D-glucose,
1 mM MgCl2, pH 7.1) at a concentration of 105 cells/ml.
Measurements of 10000 cells were taken in duplicate with the
following parameters and plotted on a log scale: Forward Scatter:
450 V, Side Scatter: 350 V and Alexa Fluor (GFP ﬂuorescence
intensity): 700 V. Data analysis was carried out using FlowJo
version 8.8.4 for Mac.2.5. Protein fractionation and Western blot
Saponin-isolated 3D7-PfHKGFP trophozoites were digitonin per-
meabilised as described previously [23] with modiﬁcations (Sup-
plementary information). Brieﬂy, for Western blotting, protein
samples (equivalent to 1.6 to 3.3  106 parasites) were loaded onto
precast 4–12% Bis-Tris NuPAGE gels, separated by electrophoresis
and transferred onto nitrocellulose membrane. Membranes were
then probed with mouse anti-GFP (1:1000) or rabbit anti-PfNT1
(1:1000) primary antibodies. Horseradish Peroxidase (HRP)-conju-
gated anti-mouse and anti-rabbit secondary antibodies were both
used at 1:10000 dilution. Additional detail is provided in Supple-
mentary information.
2.6. Quantitative real time PCR
Total parasite RNA was puriﬁed using RNeasy Mini Kit (QIA-
GEN) according to the manufacturer’s protocol for puriﬁcation of
total RNA from animal cells. cDNA was synthesised from parasite
total RNA using High Capacity cDNA Reverse Transcription Kit (Ap-
plied Biosystems). Quantitative real time PCR (qRT-PCR) were per-
formed using the LightCycler 480 Instrument (Roche) with
ornithine aminotransferase [24] designated as the housekeeper gene
(Supplementary information). The primers used for ampliﬁcation
are shown in the Supplementary information. The level of PfHK
transcript relative to that of the housekeeper gene was calculated
as previously described [25].
2.7. SYBR green I-based growth assays
The in vitro antiplasmodial activity of compounds was investi-
gated using the SYBR green I-based ﬂuorescence assay [26], with
minor modiﬁcations (Supplementary information).
2.8. Parasite accumulation of phospho-[14C]2-DG
The accumulation of phospho-[14C]2-DG into saponin-isolated
trophozoite stage parasites was measured as described previously
[16]. The data from the phospho-[14C]2-DG accumulation experi-
ment were expressed as ‘‘distribution ratio’’ – the concentration
of radiolabelled solute inside the cell ([CPM]in) relative to the con-
centration of [14C]2-DG in the extracellular solution ([CPM]out).
Distribution ratios were calculated using a trophozoite intracellu-
lar water volume of 28 femtoliters [20].
2.9. Phosphorylation of [14C]2-DG by parasite lysate
[14C]2-DG or [14C]pantothenate (included as a control) phos-
phorylation by lysates prepared from saponin-isolated trophozoite
stage parasites was assayed using the Somogyi reagent (combina-
tion of ZnSO4 and Ba(OH)2) as described recently [27]. The phos-
phorylation rate was determined by calculating the gradient of
the linear extrapolations of the curves either between the 1 and
4 min time points ([14C]2-DG) or the entire time course
([14C]pantothenate).
2.10. Statistical analysis
Statistical signiﬁcance was determined using two-tailed or one-
tailed Student’s t tests for paired or unpaired samples, as appropri-
ate. When the means of more than two populations were com-
pared, one-way analysis of variance (ANOVA) was performed.
Pairwise comparisons were made post hoc with Tukey’s multiple
comparisons test. Regression analysis was carried out using Sigma-
Plot for Windows version 11.0 (Systat Software, Inc). Unless other-
wise indicated, error values represent S.E.M.
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Previous attempts to localise PfHK have presented contradic-
tory results [12]. In this study, the native PfHK coding sequence
(Gene ID: PF3D7_0624000; [11]), without its stop codon, was
cloned into pGlux-1, directly upstream of a GFP coding sequence
and transfected into wild-type (3D7 strain) P. falciparum. To deter-
mine the proportion of ﬂuorescent parasites in the 3D7-PfHKGFP
population, FACS analysis was performed. On average, 95 ± 2%
(N = 5) of the parasites in the 3D7-PfHKGFP line were ﬂuorescent
(Fig. 1A). To elucidate the intracellular location of PfHK, wet
mounts of 3D7-PfHKGFP-infected erythrocytes were observed using
confocal microscopy. We show that GFP-associated ﬂuorescence
(green) was diffuse throughout the parasite cytosol, both in the
ring and trophozoite stages (Fig. 1B). To conﬁrm the predominantly
cytosolic location of PfHK-GFP, we carried out Western blot
analysis of the soluble and membrane-bound protein fractions of
3D7-PfHKGFP trophozoites (Fig. 1C). Protein samples from whole
parasites were also loaded as controls. Blots treated with anti-
GFP antibody indicate the presence of a single polypeptide band
of83 kDa for whole parasite and soluble protein fraction samples,
which corresponds to the predicted mass of the PfHK-GFP fusion
protein. The small amount of PfHK-GFP observed in the membrane
fraction is likely due to contamination of this fraction by cytosolic
proteins, as observed previously for other soluble proteins such as
GFP [28]. In control blots treated with an antibody against
Nucleoside Transporter 1 (PfNT1 – an integral membrane protein),
a 36 kDa band was detected (within the range of previous reports
[29,30]) in whole parasite and membrane fraction samples, and
could not be detected in the soluble protein fraction. Therefore, un-
der the conditions of our experiments, PfHK appears to be cytosolic
and is not associated with the PPM as suggested previously [12].
In order to characterise PfHK further, we generated a cell line,
‘‘3D7-PfHK+’’, overexpressing the native PfHK. A parasite line,
‘‘3D7-Plasmid’’, harbouring an empty pGlux-1 plasmid, was also
generated and used as a control. Using SYBR green I-based qRT-
PCR, we show (Fig. 2A) that 3D7-PfHK+ parasites have a 6 ± 2-fold
higher (P = 0.038) level of PfHK transcript relative to 3D7-Plasmid,
with both normalised to the housekeeper mRNA (ornithine
aminotransferase).
We then investigated the effect of PfHK overexpression on the
parasites’ sensitivity to the glycolysis-inhibiting compound 2-DG,
using doxycycline (an antimalarial with a mechanism of action
unrelated to glycolysis [31]) as a control compound. The data inFig. 1. (A) Representative FACS analysis of 3D7 and 3D7-PfHKGFP P. falciparum cell lines. 3
protein’s carboxyl end. Expression of the fusion protein is regulated by the P. falciparum c
cells was used to establish a threshold above which cells are deﬁned as ﬂuorescent (rep
ﬂuorescent cells in the population. The data shown are from a single experiment represe
confocal microscopy. Brightﬁeld, GFP-ﬂuorescence and merged images of erythrocytes in
Scale bar represents approximately 1.5 lm. (C) Western blot analysis of 3D7-PfHKGFP P. fa
proteins from the same number (and preparation) of parasites. Nitrocellulose membrane
anti-PfNT1 antibodies. Position and size (in kDa) of the reference ladder bands are indicat
experiments. (For interpretation of the references to colour in this ﬁgure legend, the reaFig. 2B illustrate the effect of doxycycline on the proliferation of
the P. falciparum lines tested. The doxycycline IC50 values (drug
concentration that inhibits parasite proliferation by 50%) for 3D7
(22 ± 2 lM), 3D7-Plasmid (27 ± 4 lM), and 3D7-PfHK+
(24 ± 1 lM) were not signiﬁcantly different from each other
(P > 0.05, one-way ANOVA with Tukey’s post-test). The effect of
2-DG on the proliferation of the P. falciparum lines is shown in
Fig. 2C. The data obtained for 3D7-PfHK+ are shifted to the right
of those obtained for the control lines. The 2-DG IC50 value for
3D7-PfHK+ (10 ± 1 mM) was approximately 2-fold higher than
the values for the control lines (3D7 = 6.3 ± 0.3 mM; 3D7-Plas-
mid = 6.1 ± 0.2 mM). This difference reached statistical signiﬁcance
(P < 0.001, one-way ANOVA with Tukey’s post-test). These results
are consistent with PfHK overexpression in 3D7-PfHK+ conferring
a protective effect against 2-DG.
To test whether PfHK overexpression would increase the rate of
glucose phosphorylation, and hence its entry into glycolysis (i.e.
whether PfHK activity is rate-limiting), we measured the uptake
and phosphorylation of [14C]2-DG in 3D7-PfHK+ and 3D7-Plasmid
parasites. We utilised [14C]2-DG instead of radiolabelled glucose
because 2-DG has been shown to be transported and phosphory-
lated through the same processes as glucose, but does not proceed
further into glycolysis [17]. The amount of radioactivity inside the
cell will therefore represent the amount of 2-DG and phospho-2-
DG accumulated within the parasites.
As shown in Fig. 3A, the accumulation of phospho-[14C]2-DG is
rapid, reaching a distribution ratio of 20 within the ﬁrst 4 min of
the time course for both 3D7-Plasmid and 3D7-PfHK+. This is con-
sistent with the ﬁndings of previous reports [17,32,5,16]. The ini-
tial rates of phospho-[14C]2-DG accumulation (determined from
the gradient of ﬁtted curves at time point ‘‘0’’) in the two cell lines
(3D7-Plasmid = 14 ± 3 distribution ratio/min; 3D7-PfHK+ = 15 ± 1
distribution ratio/min) were not signiﬁcantly different (P = 0.77).
There are two main possible explanations for this result: (i)
although PfHK is overexpressed in 3D7-PfHK+ (Fig. 2A), the level
of PfHK activity may be regulated by the parasite and/or (ii) the
rate of [14C]2-DG transport into the parasite by PfHT may be limit-
ing the rate of [14C]2-DG phosphorylation within the parasite.
To distinguish between these two possibilities, we measured
the rate of [14C]2-DG phosphorylation by parasite lysates
prepared from 3D7-PfHK+ and 3D7-Plasmid trophozoites. Fig. 3B
shows that the phosphorylation rate of [14C]2-DG by 3D7-PfHK+
lysate (3.0 ± 0.5 lmol/1012 cells/min) was approximately 3-fold
higher (P < 0.01, one-way ANOVA with Tukey’s post test) thanD7-PfHKGFP parasites episomally express PfHK that has been tagged with GFP at the
hloroquine resistance transporter promoter. The proportion of non-ﬂuorescent 3D7
resented by the pink trapezoid gates). The pink numbers indicate the percentage of
ntative of ﬁve independent experiments. (B) Localisation of GFP-tagged PfHK using
fected with two ring-stage parasites (top) and a trophozoite-stage parasite (bottom).
lciparum whole parasites (1.6 to 3.3  106 cells) and, soluble and membrane-bound
s containing samples from the same fractions were probed with either anti-GFP or
ed. The data shown are from a single experiment representative of two independent
der is referred to the web version of this article.)
Fig. 2. (A) Quantitative real-time PCR analysis of PfHK expression normalised to ornithine aminotransferase in 3D7-Plasmid (white bar) and 3D7-PfHK+ (black bar)
trophozoites. The data are averaged from four independent experiments, each performed in triplicate. The P-value was obtained from a one-tailed, unpaired Student’s t-test.
The in vitro antiplasmodial activities of (B) doxycycline and (C) 2-deoxy-D-glucose against 3D7-Plasmid (open circles), 3D7-PfHK+ (closed circles) and 3D7 (open triangles) P.
falciparum lines. The data are averaged from three and ﬁve independent experiments, respectively, each performed in triplicate. Error bars represent S.E.M. and where not
shown are smaller than the symbols.
Fig. 3. (A) The accumulation of phospho-[14C]2-deoxy-D-glucose in isolated 3D7-Plasmid (open circles) and 3D7-PfHK+ (closed circles) P. falciparum trophozoites suspended
in standard malaria saline containing 0.2 mM D-glucose. The data are averaged from three independent experiments, each performed in duplicate. (B) The phosphorylation of
[14C]2-deoxy-D-glucose and [14C]pantothenate (inset) by lysates prepared from 3D7-Plasmid and 3D7-PfHK+ trophozoites. The data are averaged from ﬁve and two
independent experiments respectively, each performed in duplicate. The [14C]pantothenate phosphorylation experiments were paired (i.e. using the same batch of lysates)
with two of the ﬁve [14C]2-deoxy-D-glucose experiments. (C) The initial rate of accumulation of phospho-[14C]2-deoxy-D-glucose by trophozoites isolated from the 3D7
(white bar) and 3D7-PfHT+ (grey bar) parasite lines. The data are averaged from four independent experiments, each performed in duplicate. The P-value was obtained from a
two-tailed, unpaired Student’s t-test. For all of the ﬁgures, error bars represent S.E.M. except for the inset where they represent range/2. Where not shown, error bars are
smaller than the symbols.
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comparison, the phosphorylation rates of [14C]pantothenate
(included as a control) by lysates isolated from 3D7-Plasmid
(0.21 ± 0.02 lmol/1012 cells/min; mean ± range/2) and 3D7-PfHK+
(0.23 ± 0.08 lmol/1012 cells/min; mean ± range/2) did not differ
markedly from each other (Fig. 3B inset). This result with panto-
thenate, therefore, conﬁrms that the observed increase in the
[14C]2-DG phosphorylation rate by 3D7-PfHK+ is not due to ele-
vated total protein/enzyme quantity between the control and PfHK
overexpressing cell lines. These results are consistent with the
3D7-PfHK+ line having the capacity for increased PfHK activity
and support the possibility that PfHT limits the rate of glucose en-
try into the parasite and, consequently, its phosphorylation. To
investigate this directly, we determined the initial rate of phos-
pho-[14C]2-DG accumulation in 3D7 and 3D7-PfHT+, a previously
generated transgenic P. falciparum line shown to overexpress PfHT
by approximately 3-fold [33]. Fig. 3C illustrates the 58 ± 9% higherinitial rate of accumulation of phospho-[14C]2-DG (P = 0.016) in
3D7-PfHT+ compared with 3D7. This supports the hypothesis that
the rate of glucose transport by PfHT limits the rate of glucose en-
try into glycolysis in P. falciparum.
4. Discussion
4.1. PfHK localisation
PfHK has been reported to possess a potential hydrophobic
membrane anchor sequence at its carboxyl terminus [10]. The
mammalian Type I hexokinase isozyme also possesses a hydropho-
bic sequence at its amino terminus, which has been shown to be
essential for its binding to the mitochondrial outer membrane
[34]. Based on this similarity, Olafsson and Certa conducted immu-
noelectron microscopy experiments using anti-PfHK antibodies
and concluded that PfHK may be associated with the PPM [12]. A
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also found a similar hydrophobicity proﬁle in the hexokinase car-
boxyl terminus that is thought to explain the enzyme’s ability to
associate weakly with the membrane [35]. It was argued that such
an arrangement would lead to more efﬁcient glucose accumula-
tion; glucose molecules taken up by the parasites via the glucose
transporter would immediately be phosphorylated by the nearby
hexokinase and thereby funnelled into glycolysis. However, some
experiments in both investigations [12,35] indicated that the
majority of hexokinase was located in the cytosol of these
parasites.
In this study, a transgenic parasite line that expresses a GFP-la-
belled PfHK was generated to investigate further the enzyme’s
location within P. falciparum. It was observed that the GFP ﬂuores-
cence was diffuse throughout the cytosol of the transgenic parasite
in both the ring and trophozoite stages, indicating a mainly cyto-
solic location of PfHK (Fig. 1B). Additionally, from the Western blot
analysis performed here, the PfHK-GFP polypeptide was detected
almost exclusively in the cytosolic parasite fraction (Fig. 1C). There
are several examples of other P. falciparum encoded proteins that
have been successfully localised to their predicted targets using
the GFP reporter system used here [36], including a GFP-tagged
protein (glideosome-associated protein 50) which, like the PfHK-
GFP construct used here, contains a transmembrane domain lo-
cated just upstream of the GFP label at the carboxyl terminus
[37]. Furthermore, previous afﬁnity chromatography experiments
involving parasite cytosolic fractions (derived from supernatants
of parasite lysates centrifuged at 100000g to remove mem-
branes), captured PfHK using immobilised baits [38,39]. This is
consistent with PfHK being a cytosolic protein, as observed in this
study.
4.2. Drug sensitivity of 3D7-PfHK+
Overexpression of target proteins is frequently utilised as a
strategy to validate potential drug targets [40]. For example, it
was shown in a study that overexpression of a leucyl aminopepti-
dase in a transgenic P. falciparum strain reduced the parasite’s sen-
sitivity to bestatin by 2.5-fold when compared with the parent
strain [41]. Using the same approach, a parasite line overexpress-
ing PfHT (the strain used in this study) was reported to be 2.5-fold
less sensitive to the PfHT-targeting inhibitor, compound 3361, than
wild-type parasites [33]. The observation in this study that para-
sites overexpressing PfHK are almost 2-fold less sensitive
(Fig. 2C) to the antiplasmodial activity of 2-DG (a known glycolysis
inhibitor) when compared with wild-type parasites and parasites
containing an ‘‘empty’’ vector, is consistent with PfHK being a po-
tential drug target. The demonstration that parasite sensitivity to
doxycycline (which has a mode of action unrelated to glycolysis
[31]) is unchanged when PfHK is overexpressed, supports the
hypothesis that the shift in 2-DG sensitivity is speciﬁcally a result
of PfHK overexpression. It has been previously shown that 2-DG
signiﬁcantly inhibits P. falciparum growth in vitro, most likely via
an effect on parasite glycolysis [16]. Therefore, the data generated
in the present study offer direct support of this hypothesis. The ex-
act mechanism through which 2-DG inhibits parasite growth, how-
ever, remains to be fully understood. In P. falciparum, it was
determined that 2-DG enters the parasite mainly through PfHT
[3], and is phosphorylated by PfHK to phospho-2-DG, which accu-
mulates within the parasite because it does not proceed further
within the glycolytic pathway [17]. A likely explanation, therefore,
would be that phospho-2-DG mediates parasite growth inhibition.
In mammalian cells, 2-DG has likewise been observed to accumu-
late in the form of phospho-2-DG [42]. It was also suggested that
phospho-2-DG inhibits the enzyme phosphohexoisomerase and
that this is the primary mechanism by which it blocks glycolysis[42]. However, more recent ﬁndings show that phospho-2-DG ex-
erts a secondary non-competitive inhibitory effect on hexokinase
[43]. Although it is possibly similar in nature to the allosteric inhi-
bition of the enzyme by glucose-6-phosphate, the concentration of
phospho-2-DG required for this purpose is much higher [43],
which may explain the apparent absence of hexokinase inhibition
by phospho-2-DG in previous studies [44].
Based on these observations, the decreased 2-DG sensitivity in
parasites overexpressing PfHK (Fig. 2C) is consistent with phos-
pho-2-DG inhibiting PfHK. The glucose analogue 2-FG, another
inhibitor of P. falciparum growth [16], was postulated to inhibit
mammalian hexokinase in the same way as glucose-6-phosphate
after it is phosphorylated to phospho-2-FG [45]. Furthermore, a re-
cent report has shown that glucose-6-phosphate inhibits heterolo-
gously-expressed PfHK [46]. From the observations in these
studies, phospho-2-DG is likely to inhibit the P. falciparum hexoki-
nase in a way that is similar to glucose-6-phosphate regulation. It
should be noted that the 3D7-PfHK+ parasite line generated here
has the potential of being used in future studies to conﬁrm the
mechanism of action of drugs that are designed to target, or are
suspected of targeting, PfHK.
4.3. Checkpoint for glucose entry into glycolysis
Prior to this study, it was not known whether PfHK overexpres-
sion would result in increased hexokinase activity or whether the
additional PfHK would be regulated to maintain hexokinase activ-
ity at a certain level. To resolve these possibilities, we measured
and compared the rates of [14C]2-DG accumulation and phosphor-
ylation by wild-type and PfHK overexpressing cell lines. It was ob-
served that there was no difference in the accumulation rates of
phospho-[14C]2-DG between the saponin-isolated 3D7-PfHK+ and
3D7-Plasmid parasites (Fig. 3A). The [14C]2-DG phosphorylation
rate by lysates prepared from 3D7-PfHK+ parasites was, however,
signiﬁcantly higher (by 3-fold) than the rate determined from ly-
sates prepared from 3D7-Plasmid parasites (Fig. 3B).
These observations can be explained simply by the transport of
glucose across the PPM being rate-limiting for glucose entry into
glycolysis. The rate of glucose transport into the parasite by PfHT
could be slower than that of PfHK-catalysed glucose phosphoryla-
tion. If this is the case, overexpression of PfHK will not cause a cor-
responding increase in the amount of glucose-6-phosphate
generated. Here, we observe that overexpression of PfHT (which
would increase the rate of glucose transport into the parasite) re-
sulted in a 1.5-fold increase in the rate of [14C]2-DG accumulation.
As 2-DG accumulation requires the coordinated action of PfHT and
PfHK, it is consistent with PfHT transport being rate-limiting for
glucose entry into glycolysis. Studies involving the bloodstream
form of Trypanosoma brucei (another protozoan parasite) have also
suggested that glucose transport is most likely the rate-limiting
step of this parasite’s glycolytic pathway [47].
In conclusion, we show that in contrast to some previous sug-
gestions, PfHK is located within the cytosol of P. falciparum. The
overexpression of PfHK reduced the parasite susceptibility to 2-
DG, consistent with PfHK being the target of its antiplasmodial
activity. This ﬁnding supports the notion that glycolysis is a viable
antimalarial drug target. Furthermore, we present evidence consis-
tent with glucose transport by PfHT limiting the rate of glucose en-
try into P. falciparum glycolysis, supporting the suitability of PfHT
as a drug target.
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